232931-57-6 | SJG-136

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$332.00	$233.00
2mg	98%	in stock	$457.00	$320.00

Description

• Catalog Number: AB22669
• Chemical Name: SJG-136
• CAS Number: 232931-57-6
• Molecular Formula: C31H32N4O6
• Molecular Weight: 556.6090
• MDL Number: MFCD19443671
• SMILES: COc1cc2c(cc1OCCCOc1cc3N=C[C@H]4N(C(=O)c3cc1OC)CC(=C)C4)N=C[C@H]1N(C2=O)CC(=C)C1
• NSC Number: 694501

Computed Properties

• Complexity: 1020
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 41
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 8
• XLogP3: 1.9

Literature

• Small molecule drugs - optimizing DNA damaging agent-based therapeutics.

  Current opinion in pharmacology 20120801

• Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats.

  Cancer chemotherapy and pharmacology 20110901

• Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110601

• The development of pyrrolobenzodiazepines as antitumour agents.

  Expert opinion on investigational drugs 20110601

• A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.

  Cancer chemotherapy and pharmacology 20100401

• Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate.

  Bioorganic & medicinal chemistry letters 20091115

• The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links.

  Journal of the American Chemical Society 20090930

• Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090315

• Remarkable enhancement in the DNA-binding ability of C2-fluoro substituted pyrrolo[2,1-c][1,4]benzodiazepines and their anticancer potential.

  Bioorganic & medicinal chemistry 20090215

• ABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136.

  The pharmacogenomics journal 20080801

• An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs.

  Bioorganic & medicinal chemistry letters 20080315

• An assay combining high-performance liquid chromatography and mass spectrometry to measure DNA interstrand cross-linking efficiency in oligonucleotides of varying sequences.

  Analytical biochemistry 20080301

• Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study.

  Journal of mass spectrometry : JMS 20080101

• Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.

  British journal of cancer 20070716

• The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.

  International journal of oncology 20061201

• DNA interstrand crosslinking agents: synthesis, DNA interactions, and cytotoxicity of dimeric achiral seco-amino-CBI and conjugates of achiral seco-amino-CBI with pyrrolobenzodiazepine (PBD).

  Bioorganic & medicinal chemistry letters 20061101

• Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates.

  Journal of medicinal chemistry 20060907

• LC-MS/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501).

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060807

• Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling.

  Molecular cancer therapeutics 20060601

• AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA.

  IDrugs : the investigational drugs journal 20060101

• Direct liquid chromatography determination of the reactive imine SJG-136 (NSC 694501).

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050805

• Influence of P-glycoprotein expression on in vitro cytotoxicity and in vivo antitumour activity of the novel pyrrolobenzodiazepine dimer SJG-136.

  European journal of cancer (Oxford, England : 1990) 20050801

• Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies.

  Biochemistry 20050322

• Synthesis of fluorinated analogues of SJG-136 and their DNA-binding potential.

  Bioorganic & medicinal chemistry letters 20041115

• SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.

  Cancer research 20040915

• SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.

  Cancer research 20040915

• The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.

  Cancer research 20040915

• Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.

  Investigational new drugs 20040801

• Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer.

  Bioorganic & medicinal chemistry letters 20011105

• Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.

  Journal of medicinal chemistry 20010301